Modulation of inflammatory processes by thermal stimulating and RPE regenerative laser therapies in age related macular degeneration mouse models.
Age- related Macular Degeneration (AMD)
Inflammation
Laser Therapies
Selective Retina Therapy (SRT)
Thermal Stimulation of the Retina (TSR)
Journal
Cytokine: X
ISSN: 2590-1532
Titre abrégé: Cytokine X
Pays: Netherlands
ID NLM: 101743248
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
30
04
2020
revised:
10
06
2020
accepted:
12
06
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Inflammatory processes play a major role within the multifactorial pathogenesis of age-related macular degeneration (AMD). Neuroretina sparing laser therapies, thermal stimulation of the retina (TSR) and selective retina therapy (SRT), are known to reduce AMD-like pathology in vitro and in vivo. We investigated the effect of TSR and SRT on inflammatory processes in AMD mouse models. One randomized eye of 8 months old apolipoprotein (Apo)E and 9 months old nuclear factor (erythroid-derived 2) -like 2 (NRF2) knock out mice were treated by TSR (10 ms, 532 nm, 50 µm The inflammatory gene expression profile of both knock out models compared to healthy BL/6J mice suggests a regulation of pro- and anti-inflammatory processes especially concerning T-cell activity and immune cell recruitment. TSR resulted in downregulation of several pro-inflammatory cell-mediators both in ApoE -/- and NRF2-/- mice compared to treatment naïve litter mates one day after treatment. In contrast, SRT induced pro-inflammatory cell-mediators connected with necrosis one day after treatment as expected following laser-induced selective RPE cell death. Seven days after laser treatment, both findings were reversed. Both TSR and SRT influence inflammatory processes in AMD mouse models. However, they act conversely. TSR leads to anti-inflammatory processes shortly after laser therapy and induces immune-cell recruitment one week after treatment. SRT leads to a quick inflammatory response to laser induced RPE necrotic processes. One week after SRT inflammation is inhibited. It remains unclear, if and to what extent this might play a role in a therapeutic or preventive approach of both laser modalities on AMD pathology.
Identifiants
pubmed: 33604557
doi: 10.1016/j.cytox.2020.100031
pii: S2590-1532(20)30011-2
pmc: PMC7885883
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100031Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2035-42
pubmed: 10892840
FASEB J. 2015 Feb;29(2):696-710
pubmed: 25392267
Biochimie. 2019 Apr;159:49-54
pubmed: 30031036
Graefes Arch Clin Exp Ophthalmol. 2016 Jun;254(6):1221-7
pubmed: 27106622
Hum Mol Genet. 2017 Aug 1;26(R1):R45-R50
pubmed: 28854576
Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):3073-3085
pubmed: 28632844
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Nat Med. 2012 May;18(5):791-8
pubmed: 22484808
Ophthalmologe. 2006 Sep;103(9):742-8
pubmed: 16924447
Lipids Health Dis. 2018 Jan 4;17(1):3
pubmed: 29301530
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):675-9
pubmed: 12525699
Exp Eye Res. 2002 Feb;74(2):301-8
pubmed: 11950240
Transl Vis Sci Technol. 2018 May 1;7(3):2
pubmed: 29736323
Arch Ophthalmol. 2001 Oct;119(10):1439-52
pubmed: 11594943
PLoS One. 2011 Apr 29;6(4):e19456
pubmed: 21559389
Ophthalmology. 2013 Apr;120(4):844-51
pubmed: 23332590
Immunol Lett. 2012 Sep;147(1-2):29-33
pubmed: 22698681
Retina. 1999;19(2):141-7
pubmed: 10213241
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
Invest Ophthalmol Vis Sci. 2014 Sep 18;55(10):6673-8
pubmed: 25237159
Exp Eye Res. 2017 Nov;164:31-36
pubmed: 28782506
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):265-74
pubmed: 11133878
Retina. 2017 May;37(5):819-835
pubmed: 27902638
Annu Rev Pathol. 2008;3:99-126
pubmed: 18039143
Cell. 2012 May 11;149(4):847-59
pubmed: 22541070
Eye (Lond). 1988;2 ( Pt 5):552-77
pubmed: 2476333
Elife. 2019 Apr 30;8:
pubmed: 31036157
Exp Eye Res. 2017 Dec;165:65-77
pubmed: 28943268
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1323-1331
pubmed: 29625455
Arch Ophthalmol. 1999 Mar;117(3):329-39
pubmed: 10088810
JAMA Ophthalmol. 2018 Jun 1;136(6):666-677
pubmed: 29801123
Int J Biochem Cell Biol. 2013 Jul;45(7):1457-67
pubmed: 23603148
Transl Vis Sci Technol. 2019 Nov 13;8(6):11
pubmed: 31737435
Nutrients. 2016 Oct 22;8(10):
pubmed: 27782072
Adv Med Sci. 2020 Mar;65(1):71-77
pubmed: 31918066
Ophthalmology. 2015 Apr;122(4):809-16
pubmed: 25542520
Invest Ophthalmol Vis Sci. 2018 Mar 20;59(4):AMD160-AMD181
pubmed: 30357336
J Lipid Res. 2017 Jul;58(7):1325-1337
pubmed: 28442497
Klin Monbl Augenheilkd. 2020 Feb;237(2):192-201
pubmed: 31049909
Basic Clin Neurosci. 2016 Oct;7(4):291-298
pubmed: 27872690
Nat Rev Immunol. 2013 Jun;13(6):438-51
pubmed: 23702979
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):523-32
pubmed: 18936140
Cell Mol Life Sci. 2016 May;73(9):1765-86
pubmed: 26852158
Transplantation. 2001 Sep 15;72(5):907-14
pubmed: 11571458
Nat Med. 2008 Feb;14(2):194-8
pubmed: 18223656
ALTEX. 2003;20(Suppl 1):63-76
pubmed: 14671703
Invest Ophthalmol Vis Sci. 1999 Feb;40(2):443-9
pubmed: 9950604
Br J Ophthalmol. 2011 Dec;95(12):1638-45
pubmed: 21890786
Mol Aspects Med. 2012 Aug;33(4):487-509
pubmed: 22705444
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Ophthalmology. 1992 Jun;99(6):933-43
pubmed: 1630784
Am J Pathol. 2010 Jun;176(6):3085-97
pubmed: 20395434
J Biol Chem. 2007 Aug 3;282(31):22414-25
pubmed: 17558024
FASEB J. 2010 Dec;24(12):4816-24
pubmed: 20686107
JAMA. 2006 Jul 19;296(3):301-9
pubmed: 16849663